Firstview Insight's Limb Girdle Muscular Dystrophy Pipeline Review2019 provides an overview of the pipeline landscape of Limb Girdle Muscular Dystrophy It provides comprehensive insights of all the clinical and nonclinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.
Limbgirdle muscular dystrophy is a term for a group of diseases that cause weakness and wasting of the muscles in the arms and legs. The muscles most affected are those closest to the body proximal muscles, specifically the muscles of the shoulders, upper arms, pelvic area, and thighs.
The severity, age of onset, and features of limbgirdle muscle dystrophy vary among the many subtypes of this condition and may be inconsistent even within the same family. Signs and symptoms may first appear at any age and generally worsen with time, although in some cases they remain mild.
In the early stages of limbgirdle muscular dystrophy, affected individuals may have an unusual walking gait, such as waddling or walking on the balls of their feet, and may also have difficulty running. They may need to use their arms to press themselves up from a squatting position because of their weak thigh muscles. As the conditionprogresses, people with limbgirdle muscular dystrophy may eventually require wheelchair assistance.
Muscle wasting may cause changes in posture or in the appearance of the shoulder, back, and arm. In particular, weak shoulder muscles tend to make the shoulder blades scapulae "stick out" from the back, a sign known as scapular winging. Affected individuals may also have an abnormally curved lower back lordosis or a spine that curves to the side scoliosis. Some develop joint stiffness contractures that can restrict movement in their hips, knees, ankles, or elbows. Overgrowth hypertrophy of the calf muscles occurs in some people with limbgirdle muscular dystrophy.
Weakening of the heart muscle cardiomyopathy occurs in some forms of limbgirdle muscular dystrophy. Some affected individuals experience mild to severe breathing problems related to the weakness of muscles needed for breathing. In some cases, the breathing problems are severe enough that affected individuals need to use a machine to help them breathe mechanical ventilation.
Intelligence is generally unaffected in limbgirdle muscular dystrophy; however, developmental delay and intellectual disability have been reported in rare forms of the disorder.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and preclinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
The report provides a competitive landscape
The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and endpoint status
The report provides the list of companies which are the most active in the pipeline
The report covers pipeline products based on various stages of development ranging from preregistration till discovery
The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action MoA; route of administration RoA; Stage of development; clinical trial status; licensing and collaboration details other developmental activities
The report features comparative analysis of product profiles based on molecule type; mechanism of action MoA; route of administration RoA
The report summarizes all the dormant and discontinued pipeline projects
The report also provides latest news for the past one year
Reasons To Buy
To identifying prominent players in the treatment landscape
To determine the drivers; barriers and unmet need in the treatment space
Gain strategically significant competitor information; analysis; and insights to formulate effective RD strategies
Define inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
List of products